



91317
P#16
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In PATENT APPLICATION OF

GLENN et al.

Appln. No. 09/337,746

Filed: June 22, 1999

FOR TRANSCUTANEOUS IMMUNIZATION WITHOUT HETEROLOGOUS
ADJUVANT

RECEIVED

JUN 11 2001

TECH CENTER 1600/2900

Group Art Unit: 1644

Examiner: M. Tung

* * * * *

June 8, 2001

SUBSTITUTE INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

Further to the Information Disclosure Statements (IDS) of January 6, February 24, and May 24, 2000, the attached Form PTO-1449 is being submitted in substitution thereof. Substitution is requested to reduce the burden on the Examiner to consider separate Form PTO-1449 that have been submitted in related patent applications and to avoid confusion when these references are printed on the face of the patent.

Related to this application are U.S. Patent Nos. 5,910,306 and 5,980,898 as well as Appln. Nos. 08/749,164; 08/896,085; 09/157,395; 09/257,188; 09/266,803; 09/309,881; 09/311,720; 09/316,069; 09/545,417; and 09/585,559. The Examiner may wish to consider these related patent file wrappers and applications in prosecution of this application.

Copies of references not submitted herewith were submitted to or cited by the Examiner in the above-described related applications. But if additional copies are needed, the Examiner is invited to contact the undersigned.

This Information Disclosure Statement (IDS) is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under 37 CFR § 1.97(f), to enable Applicants to comply fully.

Applicants responded to a restriction requirement on June 1, 2001. Therefore, a first Office Action on the merits has not yet been mailed by the Examiner. Thus, it is believed that payment of the Official fee required under 37 CFR § 1.97(c) is not required. Should the Examiner disagree, however, please charge the Official fee to our Deposit Account No. 03-3975 under Order No. 81255/254811 for which purpose this paper is submitted in duplicate.

As provided by 37 CFR §§ 1.97(g) and (h), no inference should be made that this information and the listed references are prior art merely because they have been submitted for consideration. Furthermore, no representation is being made that a search has been conducted or that this statement encompasses all possible material information.

Consideration of the foregoing and enclosures, as well as the return of a copy of the Form PTO-1449 with the Examiner's initials per M.P.E.P. § 609, are earnestly

solicited. The Examiner is invited to contact the undersigned if further information is needed.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By Paul Kokulis 43180
for Paul N. Kokulis
Reg. No. 16773
Telephone: (202) 861-3503
Facsimile: (202) 822-0944

PNK/GRT
1100 New York Avenue, N.W.
Ninth Floor – East Tower
Washington, D.C. 20005-3918
Telephone: (202) 861-3000